Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have received a consensus rating of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $26.63.
EYPT has been the subject of several research analyst reports. Chardan Capital restated a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday. Robert W. Baird dropped their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating for the company in a research report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Citigroup started coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company. Finally, Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 target price on the stock.
Get Our Latest Stock Report on EyePoint Pharmaceuticals
Institutional Investors Weigh In On EyePoint Pharmaceuticals
Hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. increased its position in shares of EyePoint Pharmaceuticals by 9.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after buying an additional 362,399 shares in the last quarter. Patient Square Capital LP bought a new stake in shares of EyePoint Pharmaceuticals in the third quarter worth about $10,882,000. Geode Capital Management LLC raised its position in shares of EyePoint Pharmaceuticals by 16.1% during the third quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock worth $9,583,000 after purchasing an additional 166,699 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of EyePoint Pharmaceuticals by 1,171.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock valued at $2,970,000 after purchasing an additional 342,516 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after purchasing an additional 197,033 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.
EyePoint Pharmaceuticals Price Performance
Shares of EYPT stock traded down $0.13 during trading hours on Thursday, hitting $6.49. 1,123,171 shares of the company's stock were exchanged, compared to its average volume of 812,855. The stock's 50-day moving average is $7.87 and its 200-day moving average is $8.80. EyePoint Pharmaceuticals has a 52 week low of $6.35 and a 52 week high of $30.99. The stock has a market cap of $442.95 million, a price-to-earnings ratio of -3.25 and a beta of 1.51.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $10.52 million during the quarter, compared to analyst estimates of $12.35 million. Equities research analysts forecast that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.
EyePoint Pharmaceuticals Company Profile
(
Get Free ReportEyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
